TipRanks
Cytokinetics (CH:KK3A)
:KK3A
Switzerland Market
KK3A
Cytokinetics
RESEARCH TOOLSreports

Cytokinetics (KK3A) Stock Forecast & Price Target

0 Followers
See the Price Targets and Ratings of:

KK3A Analyst Ratings

Strong Buy
16Ratings
Strong Buy
15 Buy
1 Hold
0 Sell
Based on 16 analysts giving stock ratings to
Cytokinetics
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

KK3A Stock 12 Month Forecast

Average Price Target

―
Based on 16 Wall Street analysts offering 12 month price targets for Cytokinetics in the last 3 months. The average price target is CHF91.54 with a high forecast of CHF121.13 and a low forecast of CHF70.52. The average price target represents a ― change from the last price of ―.
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
Highest Price TargetCHF121.13Average Price TargetCHF91.54Lowest Price TargetCHF70.52
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
RBC Capital Analyst forecast on CH:KK3A
Leonid Timashev
RBC Capital
RBC Capital
CHF92.92→CHF93.75
Buy
―
Reiterated
10/08/26
Cytokinetics price target raised to $113 from $112 at RBC CapitalCytokinetics price target raised to $113 from $112 at RBC Capital
H.C. Wainwright Analyst forecast on CH:KK3A
Joseph Pantginis
H.C. Wainwright
H.C. Wainwright
CHF116.15
Buy
―
Reiterated
10/05/26
H.C. Wainwright Reaffirms Their Buy Rating on Cytokinetics (CYTK)
Needham Analyst forecast on CH:KK3A
Serge Belanger
Needham
Needham
CHF92.92
Buy
―
Reiterated
10/05/26
Analysts Offer Insights on Healthcare Companies: CervoMed (NASDAQ: CRVO), Genmab (NASDAQ: GMAB) and Cytokinetics (NASDAQ: CYTK)
Wells Fargo Analyst forecast on CH:KK3A
Yanan Zhu
Wells Fargo
Wells Fargo
CHF87.11
Buy
―
Reiterated
10/02/26
Analysts Are Bullish on These Healthcare Stocks: Ascendis Pharma (ASND), Cytokinetics (CYTK)
Truist Financial Analyst forecast on CH:KK3A
Srikripa Devarakonda
Truist Financial
Truist Financial
CHF92.92
Buy
―
Reiterated
09/01/26
Analysts Are Bullish on These Healthcare Stocks: Cytokinetics (CYTK), Ionis Pharmaceuticals (IONS)
Evercore ISI Analyst forecast on CH:KK3A
Cory Kasimov
Evercore ISI
Evercore ISI
CHF82.97
Buy
―
Reiterated
08/31/26
Evercore ISI Remains a Buy on Cytokinetics (CYTK)
Bank of America Securities Analyst forecast on CH:KK3A
Jason Zemansky
Bank of America Securities
Bank of America Securities
CHF70.52
Hold
―
Reiterated
08/31/26
Analysts Offer Insights on Healthcare Companies: Cytokinetics (NASDAQ: CYTK) and Becton Dickinson (NYSE: BDX)
Goldman Sachs Analyst forecast on CH:KK3A
Paul Choi
Goldman Sachs
Goldman Sachs
CHF87.11
Buy
―
Reiterated
08/28/26
Analysts Are Bullish on Top Healthcare Stocks: Resmed (RMD), Cytokinetics (CYTK)
Barclays Analyst forecast on CH:KK3A
Emily Field
Barclays
Barclays
CHF91.26
Buy
―
Reiterated
08/26/26
Analysts' Top Healthcare Picks: Cytokinetics (CYTK), Summit Therapeutics (SMMT)
J.P. Morgan Analyst forecast on CH:KK3A
Tessa Romero
J.P. Morgan
J.P. Morgan
―
Buy
―
Reiterated
08/20/26
Analysts Offer Insights on Healthcare Companies: Medtronic (NYSE: MDT), Ultragenyx Pharmaceutical (NASDAQ: RARE) and Cytokinetics (NASDAQ: CYTK)
Piper Sandler Analyst forecast on CH:KK3A
Yasmeen Rahimi
Piper Sandler
Piper Sandler
CHF88.77
Buy
―
Reiterated
08/07/26
Analysts Offer Insights on Healthcare Companies: CytomX Therapeutics (NASDAQ: CTMX), Cytokinetics (NASDAQ: CYTK) and Scholar Rock Holding (NASDAQ: SRRK)
Citizens JMP Analyst forecast on CH:KK3A
Jason Butler
Citizens JMP
Citizens JMP
CHF87.11→CHF91.26
Buy
―
Reiterated
08/07/26
Cytokinetics price target raised to $110 from $105 at CitizensCytokinetics price target raised to $110 from $105 at Citizens
Stifel Nicolaus Analyst forecast on CH:KK3A
James Condulis
Stifel Nicolaus
Stifel Nicolaus
CHF89.6
Buy
―
Reiterated
08/07/26
Stifel Nicolaus Sticks to Its Buy Rating for Cytokinetics (CYTK)
B. Riley Securities Analyst forecast on CH:KK3A
Mayank Mamtani
B. Riley Securities
B. Riley Securities
CHF121.13
Buy
―
Reiterated
07/31/26
B. Riley Securities Sticks to Their Buy Rating for Cytokinetics (CYTK)
Morgan Stanley Analyst forecast on CH:KK3A
Maxwell Skor
Morgan Stanley
Morgan Stanley
CHF85.46
Buy
―
Assigned
07/23/26
Cytokinetics (CYTK) Receives a Buy from Morgan Stanley
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
RBC Capital Analyst forecast on CH:KK3A
Leonid Timashev
RBC Capital
RBC Capital
CHF92.92→CHF93.75
Buy
―
Reiterated
10/08/26
Cytokinetics price target raised to $113 from $112 at RBC CapitalCytokinetics price target raised to $113 from $112 at RBC Capital
H.C. Wainwright Analyst forecast on CH:KK3A
Joseph Pantginis
H.C. Wainwright
H.C. Wainwright
CHF116.15
Buy
―
Reiterated
10/05/26
H.C. Wainwright Reaffirms Their Buy Rating on Cytokinetics (CYTK)
Needham Analyst forecast on CH:KK3A
Serge Belanger
Needham
Needham
CHF92.92
Buy
―
Reiterated
10/05/26
Analysts Offer Insights on Healthcare Companies: CervoMed (NASDAQ: CRVO), Genmab (NASDAQ: GMAB) and Cytokinetics (NASDAQ: CYTK)
Wells Fargo Analyst forecast on CH:KK3A
Yanan Zhu
Wells Fargo
Wells Fargo
CHF87.11
Buy
―
Reiterated
10/02/26
Analysts Are Bullish on These Healthcare Stocks: Ascendis Pharma (ASND), Cytokinetics (CYTK)
Truist Financial Analyst forecast on CH:KK3A
Srikripa Devarakonda
Truist Financial
Truist Financial
CHF92.92
Buy
―
Reiterated
09/01/26
Analysts Are Bullish on These Healthcare Stocks: Cytokinetics (CYTK), Ionis Pharmaceuticals (IONS)
Evercore ISI Analyst forecast on CH:KK3A
Cory Kasimov
Evercore ISI
Evercore ISI
CHF82.97
Buy
―
Reiterated
08/31/26
Evercore ISI Remains a Buy on Cytokinetics (CYTK)
Bank of America Securities Analyst forecast on CH:KK3A
Jason Zemansky
Bank of America Securities
Bank of America Securities
CHF70.52
Hold
―
Reiterated
08/31/26
Analysts Offer Insights on Healthcare Companies: Cytokinetics (NASDAQ: CYTK) and Becton Dickinson (NYSE: BDX)
Goldman Sachs Analyst forecast on CH:KK3A
Paul Choi
Goldman Sachs
Goldman Sachs
CHF87.11
Buy
―
Reiterated
08/28/26
Analysts Are Bullish on Top Healthcare Stocks: Resmed (RMD), Cytokinetics (CYTK)
Barclays Analyst forecast on CH:KK3A
Emily Field
Barclays
Barclays
CHF91.26
Buy
―
Reiterated
08/26/26
Analysts' Top Healthcare Picks: Cytokinetics (CYTK), Summit Therapeutics (SMMT)
J.P. Morgan Analyst forecast on CH:KK3A
Tessa Romero
J.P. Morgan
J.P. Morgan
―
Buy
―
Reiterated
08/20/26
Analysts Offer Insights on Healthcare Companies: Medtronic (NYSE: MDT), Ultragenyx Pharmaceutical (NASDAQ: RARE) and Cytokinetics (NASDAQ: CYTK)
Piper Sandler Analyst forecast on CH:KK3A
Yasmeen Rahimi
Piper Sandler
Piper Sandler
CHF88.77
Buy
―
Reiterated
08/07/26
Analysts Offer Insights on Healthcare Companies: CytomX Therapeutics (NASDAQ: CTMX), Cytokinetics (NASDAQ: CYTK) and Scholar Rock Holding (NASDAQ: SRRK)
Citizens JMP Analyst forecast on CH:KK3A
Jason Butler
Citizens JMP
Citizens JMP
CHF87.11→CHF91.26
Buy
―
Reiterated
08/07/26
Cytokinetics price target raised to $110 from $105 at CitizensCytokinetics price target raised to $110 from $105 at Citizens
Stifel Nicolaus Analyst forecast on CH:KK3A
James Condulis
Stifel Nicolaus
Stifel Nicolaus
CHF89.6
Buy
―
Reiterated
08/07/26
Stifel Nicolaus Sticks to Its Buy Rating for Cytokinetics (CYTK)
B. Riley Securities Analyst forecast on CH:KK3A
Mayank Mamtani
B. Riley Securities
B. Riley Securities
CHF121.13
Buy
―
Reiterated
07/31/26
B. Riley Securities Sticks to Their Buy Rating for Cytokinetics (CYTK)
Morgan Stanley Analyst forecast on CH:KK3A
Maxwell Skor
Morgan Stanley
Morgan Stanley
CHF85.46
Buy
―
Assigned
07/23/26
Cytokinetics (CYTK) Receives a Buy from Morgan Stanley
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
ONCBeOne Medicines
OVIDOvid Therapeutics
ASNDAscendis Pharma
QNCXQuince Therapeutics
EHCEncompass Health
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Cytokinetics

3 Months
Tessa RomeroJ.P. Morgan
Success Rate
16/25 ratings generated profit
64%
Average Return
+23.93%
Copying Tessa Romero's trades and holding each position for 3 Months would result in 64.00% of your transactions generating a profit, with an average return of +23.93% per trade.
1 Year
Salim SyedMizuho Securities
Success Rate
37/53 ratings generated profit
70%
Average Return
+33.37%
Copying Salim Syed's trades and holding each position for 1 Year would result in 69.81% of your transactions generating a profit, with an average return of +33.37% per trade.
2 Years
Jason ButlerCitizens JMP
Success Rate
22/28 ratings generated profit
79%
Average Return
+29.31%
Copying Jason Butler's trades and holding each position for 2 Years would result in 78.57% of your transactions generating a profit, with an average return of +29.31% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

KK3A Analyst Recommendation Trends

Rating
Jun 26
Jul 26
Aug 26
Sep 26
Oct 26
Strong Buy
4
5
7
12
14
Buy
24
22
26
19
15
Hold
4
3
5
4
3
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
32
30
38
35
32
In the current month, KK3A has received 29 Buy Ratings, 3 Hold Ratings, and 0 Sell Ratings. KK3A average Analyst price target in the past 3 months is 91.54.
Each month's total comprises the sum of three months' worth of ratings.

KK3A Financial Forecast

KK3A Earnings Forecast

Next quarter’s earnings estimate for KK3A is -CHF1.20 with a range of -CHF1.37 to -CHF0.91. The previous quarter’s EPS was -CHF1.24. KK3A beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year KK3A has Performed in-line its overall industry.
Next quarter’s earnings estimate for KK3A is -CHF1.20 with a range of -CHF1.37 to -CHF0.91. The previous quarter’s EPS was -CHF1.24. KK3A beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year KK3A has Performed in-line its overall industry.

KK3A Sales Forecast

Next quarter’s sales forecast for KK3A is CHF33.32M with a range of CHF22.91M to CHF47.32M. The previous quarter’s sales results were CHF23.74M. KK3A beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year KK3A has Performed in-line its overall industry.
Next quarter’s sales forecast for KK3A is CHF33.32M with a range of CHF22.91M to CHF47.32M. The previous quarter’s sales results were CHF23.74M. KK3A beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year KK3A has Performed in-line its overall industry.

KK3A Stock Forecast FAQ

What is CH:KK3A’s average 12-month price target, according to analysts?
Based on analyst ratings, Cytokinetics’s 12-month average price target is 91.54.
    What is CH:KK3A’s upside potential, based on the analysts’ average price target?
    Currently there's no upside potential for CH:KK3A, based on the analysts’ average price target.
    Can I see which stocks the top-ranking analysts are rating?
    Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
      How can I follow the stock ratings of top Wall Street analysts?
      Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
        Is Cytokinetics a Buy, Sell or Hold?
        Cytokinetics has a consensus rating of Strong Buy, which is based on 15 buy ratings, 1 hold ratings and 0 sell ratings.
          What is Cytokinetics’s share price target?
          The average share price target for Cytokinetics is 91.54. This is based on 16 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
          The highest analyst share price target is CHF121.13 ,and the lowest forecast is CHF70.52. The average share price target represents N/A Increase from the current price of N/A.
            What do analysts say about Cytokinetics?
            Cytokinetics’s analyst rating consensus is a Strong Buy. This is based on the ratings of 16 Wall Streets Analysts.
              How can I buy shares of Cytokinetics?
              To buy shares of CH:KK3A, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.